Methylene Blue and Ketamine Therapy | Tovani Health
Provayblue (Methylene Blue) — MAO inhibitor (IV for methemoglobinemia; chronic low-dose nootropic use)
Verdict at Tovani Health
Not currently a candidate for at-home KAP while on methylene blue. Eligible after a 2-week washout.
Patients on active methylene blue are not candidates for at-home ketamine therapy at Tovani Health. This is an operational position, not an evidentiary claim that the combination is universally dangerous. Methylene blue is a potent MAO inhibitor at clinical doses, and chronic low-dose nootropic protocols popular in biohacking communities produce meaningful MAO inhibition as well. The FDA's published warning is about methylene blue plus serotonergic agents (SSRIs, SNRIs); ketamine is in a related but distinct category because the limiting concern is sympathomimetic, not serotonergic. Ketamine acutely raises BP via indirect catecholamine release, and MAO inhibition slows clearance of those catecholamines, theoretically raising the risk of a hypertensive episode in an unmonitored at-home setting. After 2 weeks off methylene blue under your prescriber's care, you become eligible.
If you take Provayblue regularly and are considering at-home ketamine therapy, the combination is not currently a candidate. This page covers the brief pharmacologic context and what we do at intake.
How Provayblue interacts with ketamine
Methylene blue inhibits MAO-A at clinical doses, and chronic low-dose use produces measurable MAO inhibition as well. Ketamine acutely raises BP and HR by indirectly increasing catecholamine activity (norepinephrine reuptake inhibition, central sympathetic outflow). With MAO partially inhibited, those catecholamines clear more slowly, raising the theoretical risk of a hypertensive episode. Same operational reasoning the anesthesia literature applies to MAOIs around scheduled procedures.
What we do at intake
Disclose any methylene blue use, including low-dose nootropic protocols. We do not run sessions during active use. We require at least 2 weeks off before starting KAP. We are not an enforcement service; honest disclosure lets us plan safely.
Bottom line
Patients on active methylene blue are not candidates for at-home ketamine therapy at Tovani Health. This is an operational position, not an evidentiary claim that the combination is universally dangerous. Methylene blue is a potent MAO inhibitor at clinical doses, and chronic low-dose nootropic protocols popular in biohacking communities produce meaningful MAO inhibition as well. The FDA's published warning is about methylene blue plus serotonergic agents (SSRIs, SNRIs); ketamine is in a related but distinct category because the limiting concern is sympathomimetic, not serotonergic. Ketamine acutely raises BP via indirect catecholamine release, and MAO inhibition slows clearance of those catecholamines, theoretically raising the risk of a hypertensive episode in an unmonitored at-home setting. After 2 weeks off methylene blue under your prescriber's care, you become eligible.
Frequently Asked Questions
I take low-dose methylene blue as a nootropic. Is that an issue?
Yes. Even low-dose chronic use inhibits MAO. Stop methylene blue for 2 weeks before KAP.
What would change this answer
We don’t prescribe at-home ketamine in this scenario today, but the situation can change. Talk to your prescribing physician about whether the underlying clinical picture (medication change, dose taper, indication shift, or stabilization milestone) might make you eligible later. We’re happy to revisit if your circumstances change.
For immediate mental health support, the 988 Suicide & Crisis Lifeline is available 24/7 (call or text 988).
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Safety of Ketamine Augmentation to Monoamine Oxidase Inhibitors in Treatment-Resistant Depression. Veraart JKE, Smith-Apeldoorn SY, et al.. Journal of Clinical Psychiatry. 2022. PMID: 36300995
Ketamine in MAOI-treated patients with appropriate monitoring; no adverse events.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.